Abstract
Leishmaniasis is a parasitic disease caused by protozoan genus Leishmania. It is an endemic illness that encloses 80 countries, including some of the European continent and especially in development countries. In this revision the usual therapeutical options, focusing mechanisms of action and resistance, pharmacokinetics and toxicity are discussed . Additionally, the attempts for application of other chemotherapeutical drugs, especially organometalic substances derivatives of potencial active ligands, are also cited .
| Translated title of the contribution | The importance of inorganic compounds in leishmaniasis treatment |
|---|---|
| Original language | Spanish |
| Pages (from-to) | 454-461 |
| Number of pages | 8 |
| Journal | Latin American Journal of Pharmacy |
| Volume | 26 |
| Issue number | 3 |
| State | Published - 2007 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'The importance of inorganic compounds in leishmaniasis treatment'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver